Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5440)
All Articles published online
|
Publishing Process of This Article
|
Jul 6, 2020 (publication date) through May 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Yin ZZ, Zhao ZM, Tang WB, Jiang N, Zhang KD, Song YY, Wang Y, Li CG, Gao YX, Liu R. Adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for resected pancreatic ductal adenocarcinoma: A single center experience in China. World J Clin Cases 2020; 8(13): 2778-2786 [PMID: 32742988 DOI: 10.12998/wjcc.v8.i13.2778] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v8/i13/2778.htm |
| Number | Citing Articles |
| 1 |
Victor Hugo Fonseca de Jesus, Rachel P. Riechelmann. Current Treatment of Potentially Resectable Pancreatic Ductal Adenocarcinoma: A Medical Oncologist’s Perspective. Cancer Control 2023; 30 doi: 10.1177/10732748231173212
|